The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients
National Taiwan University Hospital
The pivotal clinical data support prolonged dosing intervals of up to 14 days for routine
prophylaxis in hemophilia B patients. The majority of adult and pediatric patients using
Idelvion for routine prophylaxis had a median annualized spontaneous bleeding rate (AsBR) of
0.00. The majority (99%) of bleeding episodes were managed successfully with one or two
infusions, and 94% of bleeds were controlled with only one infusion regardless of the cause
The rationale for this study is to collect the effectiveness and safety data of severe
hemophilia B patients treated with Idelvion following institutional standard of care. It is
the aim of this study to extend the results of the clinical trial program to a broader
hemophilia B population, and to compare with current alternative factor IX treatments in
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.